As a leading biotech company focusing exclusively on early drug discovery and development services, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development.
ProBio guarantees **≥85% supercoiled plasmid DNA** for clinical programs under a **fixed-cost, GMP-compliant model**, delivering results in **three months**. The Hopewell-based company emphasizes speed, quality, and transparency in plasmid manufacturing, addressing key challenges in therapeutic development. Clinical-grade plasmids meet strict regulatory standards while reducing cost unpredictability for biopharma customers.
GenScript and NVIDIA introduce the inaugural **Life Sciences Startup PitchFest**, a competition linking early-stage AI-driven biotech startups with industry experts, investors, and partners. The event aligns with **JPM Week** to foster validation and collaboration for emerging platforms in the sector.
Bestzyme, a synthetic biology company under GenScript Biotech, has launched the world’s first fully automated smart production line for sweet proteins at its Jinan facility. The system integrates research, development, and mass production into a single, streamlined process, targeting the food and beverage industry’s demand for sugar reduction without altering taste. This marks the first global full-chain solution for sweet protein manufacturing.
GenScript reports a **27.3% revenue increase** in the first half of 2026, driven by its AI-powered drug discovery segment, which has **doubled in size**. The company’s Gene-to-Protein business now accounts for **two-thirds of total revenue** for GenScript Life Science Group. Adjusted net profit also surged **203.3%** year-over-year.
GenScript and Tamarind Bio are collaborating to integrate Tamarind Bio’s AI-driven molecular design platform with GenScript’s wet-lab expertise. The partnership accelerates drug discovery by bridging computational drug design with hands-on lab validation. Researchers gain faster access to experimental verification of AI-generated molecular concepts.
GenScript introduces the **TurboCHO™ Protein Expression Kit**, a new tool designed to accelerate antibody production for researchers and development teams. The kit claims to improve expression speed and output compared to existing solutions in its category. It targets applications in biopharmaceutical development and antibody-based therapies.
GenScript establishes an mRNA-focused hub in Europe to bolster its global research and production network. The move follows recent expansions in the U.S., positioning Europe as a key operational pillar. The company integrates advanced biotech capabilities across the transatlantic region to support mRNA-based development.